Parenteral Anticoagulation at First Medical Contact Improves Infarct Related Artery Patency in STEMI
Authors:
- Vlad BatailaVBVlad Bataila
- Nicoleta-Monica Popa-FoteaNPNicoleta-Monica Popa-Fotea
- Cosmin CojocaruCosmin Cojocaru
- Lucian CalmacLCLucian Calmac
- Cosmin MihaiCMCosmin Mihai
- Marian-Bogdan DragoescuMDMarian-Bogdan Dragoescu
- Vlad PloscaruVPVlad Ploscaru
- Mugur MarinescuMMMugur Marinescu
- Vasile IlieseVIVasile Iliese
- Anamaria-Georgiana AvramAAAnamaria-Georgiana Avram
- Raluca-Elena MitranRMRaluca-Elena Mitran
- Radu-Gabriel VatasescuRVRadu-Gabriel Vatasescu
Open Access
- 16 March 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (6) , 1710
Abstract
(1) Background: Acute ST-segment elevation myocardial infarction (STEMI) remains one of the main morbidity and mortality contributors worldwide. Its main treatment, primary percutaneous coronary intervention (pPCI), can only be performed with a high anticoagulation regimen, usually with heparin. There is still not enough evidence regarding the timing of heparin administration. (2) Methods: We conducted a multicenter observational study of 614 consecutive STEMI patients treated between 2017 and 2019. We split the population in two groups: one that received heparin at the first medical contact, as early as possible, and the second group that received heparin at the PCI capable center or in the cath lab. (3) Results: There was a significantly higher rate of infarct-related artery (IRA) patency at the time of the coronary angiogram in the pre-transfer heparin group than in the on-site heparin group, 44.7% vs. 37.3%, p = 0.042. Also, the early heparin group received shorter and wider stents. There was no difference in bleeding rates or in the in-hospital and two-year mortality rates. (4) Conclusions: Early administration of heparin leads to a higher rate of reperfusion in the IRA, before pPCI, with significant related benefits, such as better stent implantation parameters, without increased bleeding rates.Keywords
This publication has 26 references indexed in Scilit:
- Impact of stent length and diameter on 10‐year mortality in the SYNTAXES trialCatheterization and Cardiovascular Interventions, 2021
- Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter?International Journal of Cardiology, 2021
- Upstream anticoagulation for patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trialCatheterization and Cardiovascular Interventions, 2019
- Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplastyInternational Journal of Cardiology, 2015
- OCT–Defined Morphological Characteristics of Coronary Artery Spasm Sites in Vasospastic AnginaJACC: Cardiovascular Imaging, 2015
- Impact of Multiple and Long Sirolimus-Eluting Stent Implantation on 3-Year Clinical Outcomes in the j-Cypher RegistryJACC: Cardiovascular Interventions, 2010
- Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable PolymerJACC: Cardiovascular Interventions, 2009
- Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non–ST-Segment Elevation Acute Coronary SyndromesJAMA, 2004
- Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience)The American Journal of Cardiology, 2001
- High Dose Bolus Heparin as Initial Therapy Before Primary Angioplasty for Acute Myocardial Infarction: Results of the Heparin in Early Patency (HEAP) Pilot StudyJACC, 1998